The stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! About 354,624 shares traded hands or 87.09% up from the average. TrovaGene Inc (NASDAQ:TROV) has declined 21.16% since April 8, 2016 and is downtrending. It has underperformed by 26.81% the S&P500.
The move comes after 5 months negative chart setup for the $111.54M company. It was reported on Nov, 10 by Barchart.com. We have $2.86 PT which if reached, will make NASDAQ:TROV worth $15.62 million less.
Analysts await TrovaGene Inc (NASDAQ:TROV) to report earnings on November, 14. They expect $-0.32 EPS, up 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.34 actual EPS reported by TrovaGene Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
TrovaGene Inc (NASDAQ:TROV) Ratings Coverage
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded TrovaGene Inc (NASDAQ:TROV) on Tuesday, April 26 to “Sector Perform” rating. The rating was downgraded by Cantor Fitzgerald to “Hold” on Monday, April 25. The firm earned “Market Perform” rating on Tuesday, March 29 by Avondale. The stock of TrovaGene Inc (NASDAQ:TROV) earned “Neutral” rating by Piper Jaffray on Monday, April 25. The rating was downgraded by Janney Capital to “Neutral” on Friday, March 11. The stock of TrovaGene Inc (NASDAQ:TROV) earned “Buy” rating by Cantor Fitzgerald on Tuesday, September 15. Leerink Swann initiated the stock with “Outperform” rating in Friday, August 14 report.
According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.84, from 1.65 in 2016Q1. The ratio worsened, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Rhumbline Advisers has invested 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV). Alliancebernstein Limited Partnership reported 13,700 shares or 0% of all its holdings. D E Shaw last reported 0% of its portfolio in the stock. Moreover, Tci Wealth Advsr has 0.01% invested in TrovaGene Inc (NASDAQ:TROV) for 2,100 shares. Moreover, Amer has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 16,218 shares. First Heartland Consultants holds 0.01% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 22,800 shares. The United Kingdom-based Gsa Cap Prtn Limited Liability Partnership has invested 0% in TrovaGene Inc (NASDAQ:TROV). National Bank & Trust Of Montreal Can has 0% invested in the company for 13,558 shares. Morgan Stanley accumulated 0% or 436,469 shares. The New York-based Tiaa Cref Invest Mngmt Limited Liability Company has invested 0% in TrovaGene Inc (NASDAQ:TROV). Price T Rowe Associates Md, a Maryland-based fund reported 17,800 shares. Morgens Waterfall Vintiadis &, a New York-based fund reported 300,000 shares. California State Teachers Retirement owns 59,077 shares or 0% of their US portfolio. Natl Bank Of America Corp De, a North Carolina-based fund reported 1,188 shares. California Public Employees Retirement Systems holds 77,200 shares or 0% of its portfolio.
More important recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene to Present at the BIO Investor Forum in San Francisco on October 19” on October 17, 2016, also Prnewswire.com published article titled: “Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference”, Zacks.com published: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?” on January 21, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) was released by: Prnewswire.com and their article: “Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands …” with publication date: February 01, 2016.
TROV Company Profile
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.